A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2− metastatic breast cancer
Introduction: Endocrine therapy and cyclin-dependent kinase (CDK) 4/6 inhibitors (CDK4/6i) are standard treatment options for hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2–) metastatic breast cancer (MBC). However, the efficacy of standard subsequent therapi...
Main Authors: | Yi Li, Wei Li, Chengcheng Gong, Yabin Zheng, Quchang Ouyang, Ning Xie, Qing Qu, Rui Ge, Biyun Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-06-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/17588359211022890 |
Similar Items
-
Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2– advanced or metastatic breast cancer in Spain
by: Galve-Calvo E, et al.
Published: (2018-11-01) -
Real-World Palbociclib Use in HR+/HER2− Advanced Breast Cancer in Canada: The IRIS Study
by: Katie Mycock, et al.
Published: (2021-01-01) -
Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
by: B. Porte, et al.
Published: (2020-12-01) -
Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer
by: Tremblay G, et al.
Published: (2018-05-01) -
Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
by: Yi Li, et al.
Published: (2020-03-01)